Mersana Therapeutics Stock Performance
| MRSN Stock | USD 0.62 0.01 1.64% |
The company secures a Beta (Market Risk) of 2.22, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Mersana Therapeutics will likely underperform. At this point, Mersana Therapeutics has a negative expected return of -1.5%. Please make sure to verify Mersana Therapeutics' treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Mersana Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Mersana Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in February 2025. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
1 | Disposition of 6250 shares by Mohan Bala of Mersana Therapeutics subject to Rule 16b-3 | 10/25/2024 |
2 | Disposition of 1884 shares by Mohan Bala of Mersana Therapeutics at 1.9 subject to Rule 16b-3 | 10/28/2024 |
3 | Disposition of 8089 shares by Brian DeSchuytner of Mersana Therapeutics at 2.0 subject to Rule 16b-3 | 11/01/2024 |
4 | Mersana Therapeutics, Inc. Reports Q3 Loss, Tops Revenue Estimates | 11/13/2024 |
5 | Balyasny Asset Management L.P. Acquires New Stake in Mersana Therapeutics Inc | 11/14/2024 |
6 | Brokerages Set Mersana Therapeutics, Inc. Price Target at 6.00 | 11/15/2024 |
7 | Mersana Therapeutics Cyclically Adjusted Revenue per Share 0.00 - GuruFocus.com | 11/20/2024 |
8 | Verition Fund Management LLC Increases Stock Holdings in Mersana Therapeutics, Inc. - MarketBeat | 12/06/2024 |
9 | Acquisition by Ecor1 Capital, Llc of 8036688 shares of Mersana Therapeutics at 1.0E-4 subject to Rule 16b-3 | 12/19/2024 |
10 | Insider Trading | 12/20/2024 |
11 | Acquisition by Alleva Lawrence M of 12521 shares of Mersana Therapeutics at 1.4 subject to Rule 16b-3 | 01/02/2025 |
12 | Mersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin Initiation of Expansion in Triple Negative Brea... | 01/10/2025 |
13 | Disposition of 8750 shares by Mohan Bala of Mersana Therapeutics subject to Rule 16b-3 | 01/13/2025 |
14 | Disposition of 3253 shares by Mohan Bala of Mersana Therapeutics at 0.66 subject to Rule 16b-3 | 01/14/2025 |
15 | Disposition of 952 shares by Carvajal Alejandra of Mersana Therapeutics at 0.63 subject to Rule 16b-3 | 01/15/2025 |
| Begin Period Cash Flow | 129.4 M |
Mersana |
Mersana Therapeutics Relative Risk vs. Return Landscape
If you would invest 210.00 in Mersana Therapeutics on October 20, 2024 and sell it today you would lose (148.00) from holding Mersana Therapeutics or give up 70.48% of portfolio value over 90 days. Mersana Therapeutics is currently does not generate positive expected returns and assumes 8.8265% risk (volatility on return distribution) over the 90 days horizon. In different words, 78% of stocks are less volatile than Mersana, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Mersana Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Mersana Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Mersana Therapeutics, and traders can use it to determine the average amount a Mersana Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1696
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | MRSN |
Estimated Market Risk
| 8.83 actual daily | 78 78% of assets are less volatile |
Expected Return
| -1.5 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.17 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Mersana Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Mersana Therapeutics by adding Mersana Therapeutics to a well-diversified portfolio.
Mersana Therapeutics Fundamentals Growth
Mersana Stock prices reflect investors' perceptions of the future prospects and financial health of Mersana Therapeutics, and Mersana Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Mersana Stock performance.
| Return On Equity | -2.13 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | (2.14) % | ||||
| Operating Margin | (0.96) % | ||||
| Current Valuation | (47.77 M) | ||||
| Shares Outstanding | 123.53 M | ||||
| Price To Earning | (0.98) X | ||||
| Price To Book | 72.35 X | ||||
| Price To Sales | 2.18 X | ||||
| Revenue | 36.85 M | ||||
| EBITDA | (166.08 M) | ||||
| Cash And Equivalents | 225.13 M | ||||
| Cash Per Share | 2.32 X | ||||
| Total Debt | 33.83 M | ||||
| Debt To Equity | 0.28 % | ||||
| Book Value Per Share | 0.31 X | ||||
| Cash Flow From Operations | (168.88 M) | ||||
| Earnings Per Share | (0.60) X | ||||
| Total Asset | 226.06 M | ||||
| Retained Earnings | (826.36 M) | ||||
| Current Asset | 71.4 M | ||||
| Current Liabilities | 51.32 M | ||||
About Mersana Therapeutics Performance
By examining Mersana Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Mersana Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Mersana Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates for cancer patients with unmet need. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts. Mersana Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 169 people.Things to note about Mersana Therapeutics performance evaluation
Checking the ongoing alerts about Mersana Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Mersana Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Mersana Therapeutics generated a negative expected return over the last 90 days | |
| Mersana Therapeutics has high historical volatility and very poor performance | |
| Mersana Therapeutics has some characteristics of a very speculative penny stock | |
| Mersana Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 36.85 M. Net Loss for the year was (171.67 M) with loss before overhead, payroll, taxes, and interest of (113.43 M). | |
| Mersana Therapeutics currently holds about 225.13 M in cash with (168.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.32, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from simplywall.st: Disposition of 952 shares by Carvajal Alejandra of Mersana Therapeutics at 0.63 subject to Rule 16b-3 |
- Analyzing Mersana Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Mersana Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Mersana Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Mersana Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Mersana Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Mersana Therapeutics' stock. These opinions can provide insight into Mersana Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mersana Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Mersana Stock, please use our How to Invest in Mersana Therapeutics guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mersana Therapeutics. If investors know Mersana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mersana Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Mersana Therapeutics is measured differently than its book value, which is the value of Mersana that is recorded on the company's balance sheet. Investors also form their own opinion of Mersana Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Mersana Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mersana Therapeutics' market value can be influenced by many factors that don't directly affect Mersana Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mersana Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mersana Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mersana Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.